In April 2022, HOPA submitted a proposal to the Board of Pharmacy Specialties to continue to provide professional development programs for the recertification of board-certified pharmacists. With BPS's approval, HOPA is proud to provide Board Certified Oncology Pharmacy (BCOP) continuing education for another seven years. The new contract begins January 1, 2024 and runs through December 31, 2030.

Read the announcement: BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024

HOPA Provides at Least 60 BCOP CEs Each Year

Each year, HOPA provides at least 60 BCOP Continuing Education Credits for members and other board certified hematology/oncology pharmacists. Explore the latest BCOP Updates and BCOP Self-Study Releases and more!

Tools and Resources Late Breaking News

Related Articles

Read all latest news Right Pointing Arrow
Mesenchymal stromal cells
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Remestemcel-L-rknd

April 30, 2025

Erin Lexner, PharmD, BCPS, PGY-2 Oncology Pharmacy Resident, and Christine Barrett, PharmD, BCOP, Oncology Pharmacy Specialist - both from Mary Babb Randolph Cancer Center at West Virginia University Hospitals - write about remestemcel-L-rknd.

Neurofibromatosis
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Mirdametinib

April 04, 2025

Ramsey Shane, PharmD, MPH, PGY1 Pharmacy Resident, and Rebecca Pokorny, PharmD, BCPS, BCOP, Clinical Pharmacist Specialist Neuro-Oncology - both from Vanderbilt University Medical Center, Nashville, TN - write about mirdametinib (Gomekli).

Lung cancer x-ray image
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Ensartinib

March 17, 2025

Savannah Young, PharmD, PGY1 Pharmacy Resident, from Sarasota Memorial Hospital, Sarasota, FL, and Kiera Roubal, PharmD, BCOP, Clinical Oncology Pharmacist Specialist, from Medical University of South Carolina, Charleston, SC, write about ensartinib.